Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The inaugural Doug Altman scholarship will be offered to an LMIC (lower-to-middle-income country) applicant or a student.

Portrait of a man in glasses sitting using a laptop

Now in its 18th year, the Centre for Statistics in Medicine's (CSM) Randomised Controlled Trials Course provides a thorough grounding in the principles and practice of randomised controlled trials (RCTs) for evaluating healthcare interventions.

For the first time in 2020, NDORMS is offering a sponsored place for an applicant from an LMIC (lower-to-middle-income country) or a student. The Doug Altman scholarship has been established in memory of course founder Professor Doug Altman, who was an advocate for transparency in scientific research and dedicated his 40-year career to developing essential tools for better design, analysis, clarity, and reporting of clinical research.

"Back in the early noughties, I was invited to a meeting with Doug Altman, then Director of the CSM, and we decided to create a short course" said Associate Professor Ed Juszczak, Director of the National Perinatal Epidemiology Unit Clinical Trials Unit and co-founder of the RCT Course. "We wanted to share our knowledge and experiences of every aspect of a clinical trial, aiming the course at those planning an RCT or actively running one, marrying the statistics with logistics and rationale, making it understandable and accessible for all. The course has run annually in Oxford since 2003 with 631 participants to date."

The sponsorship covers the full cost of the course fee and accommodation at Merton College for the duration of the five-day course, which will run from Monday 21 to Friday 25 September 2020.

Associate Professor Jonathan Cook, Course Lead said: "The course brings together a highly experienced interdisciplinary faculty of clinicians, statisticians, trialists and trial managers, and attracts participants from a very diverse range of sectors from health professionals and trial staff, through to funders and journal editors. I'm looking forward to another wonderfully stimulating and enjoyable week, learning and thinking about randomised trials in the inspiring surroundings of Merton College."

If you would you like to be considered for the sponsored place, please contact Jacqueline Wright on rct.course@csm.ox.ac.uk for more information and to request an application form.

Similar stories

Professor Katja Simon elected to the Academy of Medical Sciences

Awards Kennedy Main

Professor of Immunology Katja Simon has been elected as a Fellow of the Academy of Medical Sciences.

3,400 different medicines used globally to treat COVID-19

Main Statistics and epidemiology

Insufficient data, and misleading recommendations led to significant early heterogeneity in global COVID-19 patient management, according to recent BMJ study

Clinical trial finds Azithromycin has no benefit against COVID-19

Main OCTRU

A clinical trial by University of Oxford researchers has confirmed that the antibiotic azithromycin has no clinical benefit in people with moderate COVID-19.

Study reveals the three most important aspects of care for hip fractures

Hip Main OCTRU Research Trauma

Older patients with hip fractures recover better if they receive treatment under the supervision of both a surgeon and a specialist in elderly care; are checked to avoid future falls; and are assessed for memory problems.

Major ERC funding awarded to Professor Michael Dustin

Awards Kennedy Main

Professor Michael Dustin and an international team of collaborators have been awarded a €10M grant from the European Research Council (ERC) to develop a new biotechnology around supramolecular attack particles (SMAPs) engineered to kill cancer cells.

The role of mAbs (neutralising monoclonal antibodies) in the fight against COVID-19

Main Research

Neutralising mAbs, a form of anti-viral medicine, are being explored as an attractive option to treat symptoms of COVID-19 and in some cases prevent infection. But what are the pros and cons of this type of treatment and what should regulators consider before granting approval?